norcarane: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9245 |
| MeSH ID | M0432330 |
| Synonym |
|---|
| butanal, 2,3-dihydroxy- |
| 14214-86-9 |
| 2,3-dihydroxybutyraldehyde |
| AKOS015840955 |
| norcarane |
| nsc143399 |
| nsc-143399 |
| bicyclo[4.1.0]heptane |
| 286-08-8 |
| FT-0656907 |
| A18576 |
| WPHGSKGZRAQSGP-UHFFFAOYSA-N |
| Q680932 |
| DTXSID10870493 |
| Excerpt | Reference |
|---|---|
| "Norcarane proved to be an excellent substrate for the diiron enzyme toluene 4-monooxygenase and its engineered isoforms, with kcat and coupling between NADH utilization and total hydroxylated products comparable to that determined for toluene, the natural substrate." | ( Fox, BG; Moe, LA, 2005) |
| "Norcarane is a substrate used to reveal the lifetime of radical intermediates formed during alkane oxidation." | ( Alexander-Ozinskas, M; Austin, RN; Bertrand, EM; Chae, JC; Danahy, M; Deng, D; Groves, JT; Moe, LA; Rozhkova-Novosad, EA; van Beilen, JB; Zylstra, GJ, 2007) |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (75.00) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||